Pfizer's vaccine trial questioned over data integrity, regulatory oversight

U.S. multinational pharmaceutical corporation Pfizer has come under pressure over alleged data fraud suspicion in its COVID-19 clinical trials, according to British medical journal The BMJ.

A former employee of Texas-based research organization Ventavia Research Group, which managed Pfizer vaccine trial sites, recently raised concerns over Pfizer's data integrity and regulatory oversight, according to the article published in the BMJ.

In the article, the former regional director of Ventavia Research Group revealed that the company "falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in its pivotal phase III trial."